Press releaseNewsfile
Kiora Pharmaceuticals
KPRX · NASDAQ
$2.33−$0.05 (−2.10%)TodayMarket closed ·
Prev close $2.38
Latest news
- Press releaseNewsfile
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
- News
Earnings Scheduled For November 7, 2025
- Press releasePRNewswire
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
- Press releaseBusiness Wire
Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Kiora Grants Senju Option to Develop and Market Vision-Restoring Drug KIO-301 in Asia
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.